Rongbo Lin

1.4k total citations
47 papers, 166 citations indexed

About

Rongbo Lin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Rongbo Lin has authored 47 papers receiving a total of 166 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 19 papers in Surgery. Recurrent topics in Rongbo Lin's work include Gastric Cancer Management and Outcomes (16 papers), Colorectal Cancer Treatments and Studies (10 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (10 papers). Rongbo Lin is often cited by papers focused on Gastric Cancer Management and Outcomes (16 papers), Colorectal Cancer Treatments and Studies (10 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (10 papers). Rongbo Lin collaborates with scholars based in China and United States. Rongbo Lin's co-authors include Nanfeng Fan, Zengqing Guo, Xiaojie Wang, Shen Zhao, Ye Yan, Fan Cai, Qingshui Wang, Jie Liu, Haitao Niu and Yao Lin and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Rongbo Lin

38 papers receiving 161 citations

Peers

Rongbo Lin

ONCOL

PRM

SURGE

Yung‐Yeh Su Taiwan

Elena Molina Roldán Spain

Bryan Peterson United States

Hao‐hao Zhong China

Sam O. Kleeman United States

In Gu South Korea

Andreas Domen Belgium

Michael Share United States

Xujing Lu China

Yung‐Yeh Su Taiwan

Rongbo Lin

144 ×2.0

ONCOL

62 ×1.0

PRM

24 ×0.5

85 ×2.1

SURGE

42 ×1.4

Citations per year, relative to Rongbo Lin Rongbo Lin (= 1×) peers Yung‐Yeh Su

Countries citing papers authored by Rongbo Lin

Since Specialization

Citations

This map shows the geographic impact of Rongbo Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rongbo Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rongbo Lin more than expected).

Fields of papers citing papers by Rongbo Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rongbo Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rongbo Lin. The network helps show where Rongbo Lin may publish in the future.

Co-authorship network of co-authors of Rongbo Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Rongbo Lin. A scholar is included among the top collaborators of Rongbo Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rongbo Lin. Rongbo Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lin, Rongbo, et al.. (2025). Erythrocyte lifespan for predicting moderate and severe anemia in advanced gastric cancer patients post-anti-tumor therapeutics: a prospective study. BMC Cancer. 25(1). 1791–1791. 1 indexed citations

Lin, Rongbo, et al.. (2025). Radiomics in rectal cancer: current status of use and advances in research. Frontiers in Oncology. 14. 1470824–1470824. 3 indexed citations

Wang, Jinfeng, Junyu Zhang, Tingting Liu, et al.. (2025). Discovery of a Targeted Prodrug System Activated by Reactive Oxygen Species to Enhance Diagnostic and Therapeutic Efficacy of Photodynamic Therapy. Journal of Medicinal Chemistry. 68(16). 17611–17623.

Song, Zhengbo, Rongbo Lin, Yuan Yuan, et al.. (2024). Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in non-small-cell lung cancer (NSCLC) with KRAS G12C mutation: Results from a phase Ib/II study.. Journal of Clinical Oncology. 42(16_suppl). 8605–8605. 4 indexed citations

Zhao, Shen, et al.. (2024). Phase I trial of apatinib and paclitaxel+oxaliplatin+5‐FU/levoleucovorin for treatment‐naïve advanced gastric cancer. Cancer Science. 115(5). 1611–1621. 4 indexed citations

Song, Erwei, Herui Yao, Meili Sun, et al.. (2024). Abstract PO2-04-03: BL-M07D1, an antibody-drug conjugate directed to HER2 in patients with locally advanced or metastatic Breast Cancer with HER2-positive/low-expression and other solid tumors: Results from a first-in-human phase 1 study. Cancer Research. 84(9_Supplement). PO2–4. 2 indexed citations

Lin, Rongbo, Jianming Xu, Rongrui Liu, et al.. (2024). An anti-EpCAM x anti-CD3 bispecific antibody, M701, for the treatment of malignant ascites due to epithelial cancer: Interim results of a prospective randomized controlled phase II trial.. Journal of Clinical Oncology. 42(16_suppl). 12060–12060. 3 indexed citations

Wang, Yakun, Jifang Gong, Rongbo Lin, et al.. (2023). First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors.. Journal of Clinical Oncology. 41(16_suppl). 3016–3016. 22 indexed citations

Zhao, Shen, Xiaofeng Li, Peicheng Lin, et al.. (2022). Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer. Frontiers in Oncology. 12. 850242–850242. 1 indexed citations

10.

Lin, Yansong, et al.. (2022). 1657P Clinical and molecular profiles of radioiodine refractory differentiated thyroid cancer. Annals of Oncology. 33. S1300–S1300. 2 indexed citations

11.

Lin, Rongbo, et al.. (2021). 1444P Intravenous (IV) patient-controlled analgesia (PCA) vs oral opioid to maintain analgesia for severe cancer pain after successful hydromorphone (HM) titration: A multi-center, phase II randomized trial (HMORCT09-2). Annals of Oncology. 32. S1077–S1077. 2 indexed citations

12.

Chen, Jie, Yanhua Zhu, Xiaohong Xu, et al.. (2020). Comprehensive profiling of genomic in 80 Chinese patients with bladder cancer.. Journal of Clinical Oncology. 38(15_suppl). e17024–e17024. 1 indexed citations

13.

Wang, Qingshui, Ye Yan, Rongbo Lin, et al.. (2020). Analysis of the expression, function, prognosis and co-expression genes of DDX20 in gastric cancer. Computational and Structural Biotechnology Journal. 18. 2453–2462. 16 indexed citations

14.

Zhao, Shen, Nanfeng Fan, Hui Li, et al.. (2020). Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study. Annals of Translational Medicine. 8(19). 1233–1233. 9 indexed citations

15.

Deng, Yujie, Xiaohui Chen, Chuanzhong Huang, et al.. (2019). EZH2/Bcl-2 Coexpression Predicts Worse Survival in Diffuse Large B-cell Lymphomas and Demonstrates Poor Efficacy to Rituximab in Localized Lesions. Journal of Cancer. 10(9). 2006–2017. 15 indexed citations

16.

Lin, Rongbo, et al.. (2018). Apatinib reverses resistance of paclitaxel-containing regimens in advanced gastric cancer: A phase II study. Annals of Oncology. 29. ix53–ix54.

17.

Lin, Rongbo, et al.. (2017). The application value of cystatin C in the early diagnosis of acute kidney injury after partial nephrectomy. 27(4). 466–469. 1 indexed citations

18.

Zhuo, Changhua, et al.. (2017). Negative lymph node count is a significant prognostic factor in patient with stage IV gastric cancer after palliative gastrectomy. Annals of Oncology. 28. v221–v221. 1 indexed citations

19.

Chen, Qiang, Rongbo Lin, Yunbin Ye, et al.. (2009). The combined administration of partially HLA-matched irradiated allogeneic lymphocytes and thalidomide in advanced renal-cell carcinoma: a case report. Medical Oncology. 27(2). 554–558. 5 indexed citations

20.

Lin, Rongbo, Nanfeng Fan, Zengqing Guo, et al.. (2008). A Phase II Study of 5-Fluorouracil/Leucovorin in Combination with Paclitaxel and Oxaliplatin as First-Line Treatment for Patients with Advanced Gastric Cancer. Journal of Chemotherapy. 20(6). 744–748. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact